Showing results (91-100 of 119) with videos related to

Sort By:
Pageof 12
Blood|April 15, 2022
Long-term outcomes for ibrutinib-rituximab and chemoimmunotherapy in CLL: updated results of the E1912 trialTait D Shanafelt, Xin Victoria Wang, Curtis A Hanson, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 19, 2022
Adding Umbralisib and Ublituximab (U2) to Ibrutinib in Patients with CLL: A Phase II Study of an MRD-Driven ApproachLindsey E Roeker, Tatyana A Feldman, Jacob D Soumerai, et al.
Haematologica|February 9, 2018
Toxicities and outcomes of 616 ibrutinib-treated patients in the United States: a real-world analysisAnthony R Mato, Chadhi Nabhan, Meghan C Thompson, et al.
Blood Cancer Discovery|November 15, 2021
Disease- and Therapy-Specific Impact on Humoral Immune Responses to COVID-19 Vaccination in Hematologic MalignanciesDavid J Chung, Gunjan L Shah, Sean M Devlin, et al.
Blood|August 18, 2021
Measurable residual disease does not preclude prolonged progression-free survival in CLL treated with ibrutinibXin Victoria Wang, Curtis A Hanson, Renee C Tschumper, et al.
British Journal of Haematology|November 5, 2019
The efficacy and safety of venetoclax therapy in elderly patients with relapsed, refractory chronic lymphocytic leukaemiaToby A Eyre, Lindsey E Roeker, Christopher P Fox, et al.
Blood Advances|March 29, 2022
Anti-CD19 CAR T cells in combination with ibrutinib for the treatment of chronic lymphocytic leukemiaSaar Gill, Vanessa Vides, Noelle V Frey, et al.
Cancer Discovery|July 10, 2019
Altered Nuclear Export Signal Recognition as a Driver of OncogenesisJustin Taylor, Maria Sendino, Alexander N Gorelick, et al.
Blood|September 24, 2013
Donor-derived CD19-targeted T cells cause regression of malignancy persisting after allogeneic hematopoietic stem cell transplantationJames N Kochenderfer, Mark E Dudley, Robert O Carpenter, et al.
Blood Advances|August 26, 2020
Allogeneic stem cell transplantation for chronic lymphocytic leukemia in the era of novel agentsLindsey E Roeker, Peter Dreger, Jennifer R Brown, et al.
Pageof 12